Gilbert Syndrome: The Genetic Condition That May Protect Your Heart

What if a "disorder" that causes occasional yellowing of your eyes actually cut your risk of dying from heart disease in half? That's the paradox of Gilbert syndrome - the most common inherited cause of elevated bilirubin, carried by up to 10% of the population, and increasingly recognized as something closer to a genetic advantage than a disease (Horsfall et al., 2012).

If your blood tests have ever shown high bilirubin levels with no explanation, or if a doctor once told you not to worry about mild jaundice, you may carry a variant in the UGT1A1 gene. Here's what the science says - and why this "benign" condition matters more than most doctors realize.

What Is Gilbert Syndrome?

Gilbert syndrome (pronounced zheel-BARE) is a genetic condition where your liver processes bilirubin - a yellow pigment produced when red blood cells break down - about 30% slower than normal (Bosma et al., 1995). The result is mildly elevated unconjugated bilirubin in your blood, typically between 1.5 and 3.0 mg/dL instead of the usual range below 1.2 mg/dL.

For most people, this causes no symptoms at all. Some experience intermittent jaundice - a yellowish tinge to the whites of the eyes or skin - triggered by fasting, stress, dehydration, illness, or intense exercise (Fretzayas et al., 2012). The jaundice fades on its own and causes no liver damage. Your liver is structurally normal; it simply runs one specific enzyme at reduced speed.

Gilbert syndrome affects between 4% and 16% of the global population depending on ethnicity, with prevalence around 2–10% in European populations and up to 16% in parts of Africa (Wagner et al., 2018). Men are diagnosed about twice as often as women, partly because testosterone inhibits bilirubin clearance while estrogen enhances it (Strassburg, 2010).

The Gene Behind It: UGT1A1

The enzyme responsible for processing bilirubin is called bilirubin-UDP-glucuronosyltransferase, encoded by the UGT1A1 gene on chromosome 2. This enzyme adds a sugar molecule (glucuronic acid) to bilirubin, making it water-soluble so your liver can excrete it into bile (Bosma et al., 1995).

In Gilbert syndrome, the most common genetic variant is UGT1A1*28 (also tracked by the rsID rs8175347). Normal individuals have six TA repeats in the gene's promoter region - written as (TA)6TAA. People with Gilbert syndrome carry seven repeats: (TA)7TAA. This extra repeat reduces how efficiently the gene is transcribed, cutting enzyme activity by roughly 70% in homozygous individuals (Beutler et al., 1998).

Here's what your genotype means:

• UGT1A1*1/*1 - (TA)6/(TA)6 - Normal enzyme activity. Typical bilirubin levels.
• UGT1A1*1/*28 - (TA)6/(TA)7 - One copy. Mildly reduced activity. Bilirubin may be slightly elevated but usually within normal range.
• UGT1A1*28/*28 - (TA)7/(TA)7 - Two copies. This is the classic Gilbert syndrome genotype with ~30% of normal enzyme activity and visibly elevated bilirubin (Bosma et al., 1995).

The *28 allele is common: it appears in about 26–31% of Europeans, 42–45% of African Americans, and 9–16% of East Asians (Dean, 2018). In populations of African descent, a different variant - UGT1A1*37 with eight TA repeats - can also cause Gilbert syndrome (Beutler et al., 1998).

The Surprise: Bilirubin as a Cardiovascular Shield

For decades, doctors dismissed Gilbert syndrome as clinically irrelevant. Then the epidemiological data started telling a different story.

A landmark study by Horsfall et al. (2012) followed over 4,000 individuals and found that people with Gilbert syndrome had a 50% reduction in all-cause mortality compared to the general population - 24 deaths per 10,000 person-years versus 50. The primary driver? A dramatic reduction in cardiovascular death.

The mechanism centers on bilirubin's potent antioxidant properties. At physiological concentrations, bilirubin scavenges reactive oxygen species (ROS) more effectively than vitamin E (Stocker et al., 1987). Each 1 µmol/L increase in serum bilirubin has been associated with approximately a 6.5% decrease in cardiovascular disease risk (Novotný & Vítek, 2003).

Multiple pathways explain this protection:

• Antioxidant activity - Bilirubin neutralizes peroxyl radicals and protects LDL cholesterol from oxidation, a critical early step in atherosclerosis (Stocker et al., 1987).
• Anti-inflammatory effects - Elevated bilirubin reduces levels of C-reactive protein and inhibits the complement cascade (Vítek et al., 2002).
• Anti-thrombotic properties - Bilirubin appears to inhibit platelet activation, reducing the risk of blood clot formation in arteries (Bulmer et al., 2015).
• Endothelial protection - Bilirubin preserves the function of blood vessel linings, improving vascular health (Maruhashi et al., 2019).

A meta-analysis confirmed that mildly elevated bilirubin levels are consistently associated with reduced risk of ischemic heart disease, stroke, and peripheral artery disease (Lan et al., 2024). Gilbert syndrome, it turns out, may be one of evolution's quiet cardiovascular gifts.

The Drug Metabolism Connection

Here's where Gilbert syndrome stops being purely academic and becomes medically actionable: the same UGT1A1 enzyme that processes bilirubin also metabolizes certain medications.

The most critical example is irinotecan (Camptosar), a chemotherapy drug used for colorectal cancer. Irinotecan's active metabolite, SN-38, is cleared from the body by UGT1A1. In people with the *28/*28 genotype, SN-38 accumulates to dangerously high levels, causing severe neutropenia (a life-threatening drop in white blood cells) and diarrhea in up to 50% of patients at standard doses (Innocenti et al., 2004).

The FDA now includes a pharmacogenomic warning on the irinotecan label, recommending UGT1A1 genotyping before treatment. Patients who are homozygous for *28 typically receive a reduced starting dose - often 25–30% lower - to avoid toxicity (Toffoli et al., 2010).

Other drugs affected by UGT1A1 activity include:

• Atazanavir (HIV medication) - can cause pronounced jaundice in Gilbert syndrome patients (Zhang et al., 2007)
• Belinostat (cancer drug) - FDA recommends dose reduction for *28/*28 carriers
• Acetaminophen (paracetamol) - metabolism may be slightly altered, though clinical significance is debated (Court, 2010)

If you carry the Gilbert syndrome genotype, uploading your raw DNA data to GenomeInsight can flag these drug interactions before they become a problem. Our pharmacogenomics report covers UGT1A1 along with dozens of other drug-gene pairs.

What Triggers Gilbert Syndrome Episodes?

If you have Gilbert syndrome, you may notice your eyes look slightly yellow during certain situations. Common triggers include:

• Fasting or skipping meals - caloric restriction is the most reliable trigger, which is why bilirubin levels are often checked after an overnight fast (Fretzayas et al., 2012)
• Dehydration - reduced fluid intake concentrates bilirubin
• Intense exercise - prolonged exertion can temporarily increase red blood cell breakdown
• Illness or infection - physiological stress raises bilirubin production
• Sleep deprivation - disrupted circadian rhythms affect liver metabolism
• Menstruation - hormonal fluctuations alter bilirubin clearance in some women

These episodes are harmless and self-limiting. No treatment is needed in the vast majority of cases (Strassburg, 2010).

What You Can Do With This Information

If you think you have Gilbert syndrome:

1. Check your lab work. Look for unconjugated (indirect) bilirubin above 1.2 mg/dL with normal liver enzymes (ALT, AST, alkaline phosphatase). If you've had this pattern repeatedly, Gilbert syndrome is the most likely explanation.

2. Get genotyped. A DNA test - including consumer tests from 23andMe or AncestryDNA - can identify UGT1A1*28. Upload your raw data to GenomeInsight for a detailed analysis including this variant.

3. Tell your doctors. This matters most if you're ever prescribed irinotecan, atazanavir, or belinostat. A Gilbert syndrome diagnosis in your chart could prevent a dangerous adverse drug reaction.

4. Don't treat it. Gilbert syndrome requires no medication, dietary changes, or monitoring. The mildly elevated bilirubin appears to be protective, not harmful.

5. Stay informed. Subscribe to the GenomeInsight newsletter for updates on how genetic variants like UGT1A1*28 affect health and medication safety.

Key Takeaways

• Gilbert syndrome affects 4–16% of people worldwide and is caused by the UGT1A1*28 variant - an extra TA repeat that reduces bilirubin processing by ~70%.
• The condition is benign - mild jaundice during fasting or stress is the only symptom, and no treatment is needed.
• Elevated bilirubin acts as a powerful antioxidant, and Gilbert syndrome carriers show up to 50% lower all-cause mortality, driven by cardiovascular protection.
• The same enzyme variant alters drug metabolism, particularly for the chemotherapy drug irinotecan. FDA labeling recommends genotyping before treatment.
• Knowing your UGT1A1 genotype helps you understand your pharmacogenomic profile and make informed decisions about medication safety.
• Check your DNA for Gilbert syndrome and 500+ other variants with GenomeInsight's free analysis tool.

References

Beutler, E., Gelbart, T., & Demina, A. (1998). Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proceedings of the National Academy of Sciences, 95(14), 8170–8174.

Bosma, P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., ... & Jansen, P. L. (1995). The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. New England Journal of Medicine, 333(18), 1171–1175.

Bulmer, A. C., Bakrania, B., Du Toit, E. F., Boon, A. C., Clark, P. J., Powell, L. W., ... & Wagner, K. H. (2015). Bilirubin acts as a multipotent guardian of cardiovascular integrity: More than just a radical idea. American Journal of Physiology-Heart and Circulatory Physiology, 315(3), H429–H447.

Court, M. H. (2010). Interindividual variability in hepatic drug glucuronidation: Studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metabolism Reviews, 42(1), 209–224.

Dean, L. (2018). Irinotecan therapy and UGT1A1 genotype. In Medical Genetics Summaries. National Center for Biotechnology Information.

Fretzayas, A., Moustaki, M., Liapi, O., & Karpathios, T. (2012). Gilbert syndrome. European Journal of Pediatrics, 171(1), 11–15.

Horsfall, L. J., Nazareth, I., & Petersen, I. (2012). Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation, 126(22), 2556–2564.

Innocenti, F., Undevia, S. D., Iyer, L., Chen, P. X., Das, S., Kocherginsky, M., ... & Ratain, M. J. (2004). Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. Journal of Clinical Oncology, 22(8), 1382–1388.

Lan, Y., Liu, H., Liu, J., Zhao, H., & Wang, H. (2024). Is bilirubin a protective factor for cardiovascular disease? A systematic review and meta-analysis. Medicine, 103(6), e37114.

Maruhashi, T., Kihara, Y., & Higashi, Y. (2019). Bilirubin and endothelial function. Journal of Atherosclerosis and Thrombosis, 26(8), 688–696.

Novotný, L., & Vítek, L. (2003). Inverse relationship between serum bilirubin and atherosclerosis in men: A meta-analysis of published studies. Experimental Biology and Medicine, 228(5), 568–571.

Stocker, R., Yamamoto, Y., McDonagh, A. F., Glazer, A. N., & Ames, B. N. (1987). Bilirubin is an antioxidant of possible physiological importance. Science, 235(4792), 1043–1046.

Strassburg, C. P. (2010). Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome). Best Practice & Research Clinical Gastroenterology, 24(5), 555–571.

Toffoli, G., Cecchin, E., Gasparini, G., D'Andrea, M., Gattei, V., Basso, U., ... & Mini, E. (2010). Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 28(5), 866–871.

Vítek, L., Jirsa, M., Brodanová, M., Kalab, M., Marecek, Z., Danzig, V., ... & Fejfar, T. (2002). Gilbert syndrome and ischemic heart disease: A protective effect of elevated bilirubin levels. Atherosclerosis, 160(2), 449–456.

Wagner, K. H., Shiels, R. G., Lang, C. A., Seyed Khoei, N., & Bulmer, A. C. (2018). Diagnostic criteria and contributors to Gilbert's syndrome. Critical Reviews in Clinical Laboratory Sciences, 55(2), 129–139.

Zhang, D., Chando, T. J., Everett, D. W., Parise, C. J., & Humphreys, W. G. (2007). In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metabolism and Disposition, 33(11), 1729–1739.

---

Related Reading

• heart disease genetic risk